SCHEMBL7804289

SCHEMBL7804289

FC(F)(F)c1cc(Cl)ccc1CCl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLQ O75417 1/20 0.47
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
RAB9A P51151 2/20 0.40
CYP2D6 P10635 1/20 0.40
SLC6A4 P31645 2/20 0.39
HTR2A P28223 1/20 0.39
KCNH2 Q12809 1/20 0.39
IDO1 P14902 3/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
P2RX7 Q99572 2/20 0.37
GPR183 P32249 1/20 0.37
HTT P42858 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11603196 0.85 POLQ (0.48) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL5509961 0.85 RXRA (0.40) POLQHTTKDM4EALDH1A1NR1H2
SCHEMBL12682526 0.83 POLQ (0.50) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL936487 0.83 NOS3 (0.48) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL192931 0.82 POLQ (0.46) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL805479 0.82 POLQ (0.52) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL29465609 0.82 POLQ (0.46) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL1693375 0.82 POLQ (0.46) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL30098378 0.82 POLQ (0.46) POLQCYP1A2CYP2C19RAB9ACYP2D6
SCHEMBL119225 0.82 POLQ (0.46) POLQCYP1A2CYP2C19RAB9ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253548-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-08-19 US disclosed
US-10899732-B2 Substituted benzamides useful as sodium channel blockers GENENTECH, INC. (US) 2021-01-26 US disclosed
US-20180346441-A1 SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS GENENTECH, INC. (US) 2018-12-06 US disclosed
EP-2945932-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-11-21 EP disclosed
CN-108495851-A Substituted benzamide and its application method 基因泰克公司 2018-09-04 CN disclosed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US disclosed
EP-2945932-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2015-11-25 EP disclosed
CN-105008331-A COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC 2015-10-28 CN disclosed
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2015-03-19 US disclosed
US-8859606-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2014-10-14 US disclosed
WO-2014113814-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-07-24 WO disclosed
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-05-23 US disclosed
JP-2001097937-A METHOD FOR PRODUCING 4-FLUORO-2- TRIFLUOROMETHYLBENZONITRILE CENTRAL GLASS CO LTD 2001-04-10 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 POLQ 4778/4885CYP1A2 482/4885CYP2C19 842/4885
US-20180346441-A1 SUBSTITUTED BENZAMIDES USEFUL AS SODIUM CHANNEL BLOCKERS SCN2B, SCN1B, CACNA1E POLQ 4270/4885CYP1A2 864/4885CYP2C19 1754/4885
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 POLQ 4778/4885CYP1A2 482/4885CYP2C19 842/4885
US-10899732-B2 Substituted benzamides useful as sodium channel blockers SCN2B, SCN1B, CACNA1E POLQ 4270/4885CYP1A2 864/4885CYP2C19 1754/4885
US-20210253548-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF RDX, RRM1, BRIX1 POLQ 2523/4885CYP1A2 55/4885CYP2C19 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.